Filtered By:
Cancer: Gastric (Stomach) Cancer
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 294 results found since Jan 2013.
Measuring Ambulation, Motor, and Behavioral Outcomes with Poststroke Fluoxetine in Tanzania: The Phase II MAMBO Trial
Am J Trop Med Hyg. 2021 Dec 6:tpmd210653. doi: 10.4269/ajtmh.21-0653. Online ahead of print.ABSTRACTWe test the safety of fluoxetine postischemic stroke in sub-Saharan Africa. Adults with acute ischemic stroke, seen <14 days since new-onset motor deficits, were enrolled from November 2019 to October 2020 in a single-arm, open-label phase II trial of daily fluoxetine 20 mg for 90 days at Muhimbili National Hospital, Dar es Salaam, Tanzania. The primary outcome was safety with secondary outcomes of medication adherence and tolerability. About 34 patients were enrolled (11 were female; mean age 52.2 years, 65% < 60 year...
Source: Am J Trop Med Hyg - December 6, 2021 Category: Infectious Diseases Authors: Farrah Mateen Emmanuel Massawe Notburga Mworia Seif Ismail Dylan Rice Andre Vogel Boniface Kapina Novath Mukyanuzi Deus Buma Jef Gluckstein Michael Wasserman Susan Fasoli Faraja Chiwanga Kigocha Okeng'o Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Analysis of the Occurrence of Diseases Following Gastrectomy for Early Gastric Cancer: a Nationwide Claims Study
CONCLUSIONS: This study identifies diseases that may occur after gastrectomy in patients with gastric cancer.PMID:34691812 | PMC:PMC8505120 | DOI:10.5230/jgc.2021.21.e29
Source: Journal of Gastric Cancer - October 25, 2021 Category: Gastroenterology Authors: Ho Seok Seo Yewon Na Jaehun Jung Source Type: research
